



Lyka Labs Limited

MANUFACTURERS OF PHARMACEUTICALS.

Administrative Office: 101, Shiv Shakti Industrial Estate, Sir. M. V. Road, Andheri (E), Mumbai-400 059

Registered Office: 4801/B & 4802/A, G.I.D.C Industrial Estate, Ankleshwar-393 002.

CIN: L2430GJ1976PLC008738

EXTRACT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER/HALF YEAR ENDED 31ST DEC, 2015

(₹ in Lakhs)

Sr. No.	Particular	Quarter ended	Six Months Ended	Corresponding Quarter Ended
		31-Dec-15 (Unaudited)	31-Dec-15 (Unaudited)	31-Dec-14 (Unaudited)
1	Total Income from operations (Net)	3,073.01	6,611.82	4,779.82
2	Net Profit/(Loss) from ordinary activities after Tax	14.39	1,808.35	(538.78)
3	Net Profit/(Loss) for the period after Tax (after Extra ordinary items)	14.39	1,808.35	(538.78)
4	Paid Up Equity Share Capital (Face value of ₹10/- Share)	2204.00	2204.00	2158.00
5	Reserve excluding Revaluation Reserve as shown in the balance sheet of previous year	0	0	0
6	Earning per share in ₹ (before Extraordinary items) of ₹10 each			
	Basic	0.23	6.40	(2.74)
	Diluted	0.23	6.40	(2.74)
7	Earning per share in ₹ (after Extraordinary items) of ₹10 each			
	Basic	0.23	6.40	(2.74)
	Diluted	0.23	6.40	(2.74)

Notes:

- The above is an extract of the detailed format of quarterly/Half yearly Financial results filed with the stock Exchange under Regulation 33 of the SEBI (Listing and other disclosure requirements) Regulations, 2015. The full format of quarterly/Half yearly Financial results are available on the Stock Exchange Websites. (www.nseindia.com, www.bseindia.com)
- The results have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company along with Limited Review Report carried out by the Auditors at its meeting held on 12th February, 2016.
- During the quarter, the Holding Company has charged ₹ 21.41 lacs to Statement of Profit & Loss, being depreciation on revalued assets.
- During the Quarter, the Holding Company has capitalised interest of ₹ 20.68 lacs and allocable expenses of ₹ 5.02 lacs towards Ankleshwar Unit Expansion / Upgradation.
- Current Quarter Figures are not comparable as Company's one of the subsidiaries had sold on slump sale basis its Animal Healthcare Division in the previous quarter.
- The Company has one Single Segment "Pharmaceuticals".
- Information's on standalone Results

₹ in Lacs

Sr. No.	Particular	Quarter ended	Six Months Ended	Corresponding Quarter Ended
		31-Dec-15 (Unaudited)	31-Dec-15 (Unaudited)	31-Dec-14 (Unaudited)
1	Total Income from operations (Net)	1813.30	3871.99	2262.81
2	Net Profit/(Loss) before Tax	44.19	362.84	(684.97)
3	Net Profit/(Loss) after Tax	44.19	362.84	(684.97)

- Figures for previous period have been regrouped/rearranged wherever necessary to confirm to the relevant current period classification.

For LYKA LABS LIMITED

(N. I. GANDHI)

Chairman & Managing Director

DIN: 0002130

Mumbai
12th February, 2016

Ad size: 12(w) x 20(h)

Handwritten signature and initials.